Fig. 1.

WBP2, a novel modulator of AKI and ferroptosis, participated in the occurrence of CP-AKI. A The identification of WGCNA co-expression modules; B The determination of the clinical features of AKI; C The correlation analysis of the genes in all modules and the clinical features of AKI; D The network map of Brown and black modules; E The merging of WGCNA network and ferroptosis-related gene network, and the identification of WBP2 as the hub gene; F The downregulation of WBP2 in kidneys of AKI patients; G-H Western blot studies revealed that the expression of WBP2 was decreased in cisplatin-treated BUMPT cells and kidneys. DMF: dimethylformamide, CP: cisplatin. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)